Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.

Isbary G, Staab TR, Amelung VE, Dintsios CM, Iking-Konert C, Nesurini SM, Walter M, Ruof J.

Value Health. 2018 Jun;21(6):698-706. doi: 10.1016/j.jval.2017.09.010. Epub 2017 Nov 7.

PMID:
29909875
2.

Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.

Schlander M, Dintsios CM, Gandjour A.

Value Health. 2018 May;21(5):525-531. doi: 10.1016/j.jval.2017.10.015. Epub 2017 Nov 27. Review.

PMID:
29753348
3.

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.

Herpers M, Dintsios CM.

Eur J Health Econ. 2018 Apr 25. doi: 10.1007/s10198-018-0981-3. [Epub ahead of print]

PMID:
29696458
4.

Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.

Niehaus I, Dintsios CM.

Health Policy. 2018 Jun;122(6):599-606. doi: 10.1016/j.healthpol.2018.03.017. Epub 2018 Mar 26.

PMID:
29605527
5.

INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.

Dintsios CM, Schlenkrich S.

Int J Technol Assess Health Care. 2018 Jan;34(2):196-204. doi: 10.1017/S0266462317004536. Epub 2018 Feb 19.

PMID:
29455689
6.

Longterm persistence and nonrecurrence of depression treatment in Germany: a four-year retrospective follow-up using linked claims data.

Wagner CJ, Dintsios CM, Metzger FG, L'Hoest H, Marschall U, Stollenwerk B, Stock S.

Int J Methods Psychiatr Res. 2018 Jun;27(2):e1607. doi: 10.1002/mpr.1607. Epub 2018 Feb 15.

PMID:
29446186
7.

External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review.

Ogurtsova K, Heise TL, Linnenkamp U, Dintsios CM, Lhachimi SK, Icks A.

Syst Rev. 2017 Dec 29;6(1):267. doi: 10.1186/s13643-017-0664-7.

8.

[Checklist for the Development and Assessment of Cost-of-Illness Studies].

Müller D, Stock S, Dintsios CM, Chernyak N, Gerber-Grote A, Gloede TD, Hermann B, Huppertz E, Jülich F, Mostardt S, Köberlein-Neu J, Prenzler A, Salize HJ, Santos S, Scheckel B, Seidl A, Wahlers K, Icks A.

Gesundheitswesen. 2017 May 18. doi: 10.1055/s-0042-124664. [Epub ahead of print] German.

PMID:
28521377
9.
10.
11.

Letter to the editor of the Journal of Affective Disorders: Supporting the guideline's quest for real direct costs of depression care.

Dintsios CM, Wagner CJ.

J Affect Disord. 2017 Jan 15;208:101-102. doi: 10.1016/j.jad.2016.08.072. Epub 2016 Oct 11. No abstract available.

PMID:
27769004
12.
13.
14.

Direct costs in impaired glucose regulation: results from the population-based Heinz Nixdorf Recall study.

Bächle C, Claessen H, Andrich S, Brüne M, Dintsios CM, Slomiany U, Roggenbuck U, Jöckel KH, Moebus S, Icks A.

BMJ Open Diabetes Res Care. 2016 May 25;4(1):e000172. doi: 10.1136/bmjdrc-2015-000172. eCollection 2016.

15.

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Mühlbacher AC, Bridges JF, Bethge S, Dintsios CM, Schwalm A, Gerber-Grote A, Nübling M.

Eur J Health Econ. 2017 Mar;18(2):155-165. doi: 10.1007/s10198-016-0763-8. Epub 2016 Feb 4.

PMID:
26846922
16.

Re: Patient and physician preferences for the treatment of chronic hepatitis C virus infections: does the perspective matter? (Eur J Gastroenterol Hepatol 2015, 27:1063-1068).

Dintsios CM.

Eur J Gastroenterol Hepatol. 2016 Mar;28(3):362. doi: 10.1097/MEG.0000000000000554. No abstract available.

PMID:
26825146
17.

Implementation of a Multicomponent intervention to Prevent Physical Restraints In Nursing home residenTs (IMPRINT): study protocol for a cluster-randomised controlled trial.

Abraham J, Möhler R, Henkel A, Kupfer R, Icks A, Dintsios CM, Haastert B, Meyer G, Köpke S.

BMC Geriatr. 2015 Jul 21;15:86. doi: 10.1186/s12877-015-0086-0.

18.

When suddenly the evaluation became a validation.

Dintsios CM, Niederstadt C.

J Clin Epidemiol. 2016 Jan;69:257-9. doi: 10.1016/j.jclinepi.2015.06.007. Epub 2015 Jun 18. No abstract available.

PMID:
26093312
19.

Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): study protocol for a cluster-randomised controlled trial.

Richter C, Berg A, Fleischer S, Köpke S, Balzer K, Fick EM, Sönnichsen A, Löscher S, Vollmar HC, Haastert B, Icks A, Dintsios CM, Mann E, Wolf U, Meyer G.

Implement Sci. 2015 Jun 4;10:82. doi: 10.1186/s13012-015-0268-3.

20.

[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review].

Rasch A, Dintsios CM.

Z Evid Fortbild Qual Gesundhwes. 2015;109(1):69-78. doi: 10.1016/j.zefq.2015.01.001. Epub 2015 Feb 7. Review. German.

PMID:
25839372

Supplemental Content

Loading ...
Support Center